LUGANO, Switzerland, December 22, 2010 /PRNewswire/ -- Helsinn Birex Pharmaceuticals Ltd, has been assigned world-wide rights, title and interest in Klean-Prep(R), excluding Canada, and an exclusive license for the U.S.

Helsinn, a pharmaceutical group based in Lugano, Switzerland today announced that it has entered into an agreement and has been assigned by Helix BioPharma Corp., world-wide rights, title and interest, excluding Canada, and an exclusive license for the US for Klean-Prep(R), a pre-treatment for colon examination in colorectal cancer screening. Helsinn currently has a royalty-bearing license from Helix to sell Klean-Prep(R) world-wide, excluding the U.S. and Canada.

Helix will retain the Canadian rights to Klean-Prep(R). Helsinn and Helix have entered into a new supply agreement for Helsinn to supply Klean-Prep(R) to Helix with terms extending over a ten year period, subject to certain performance conditions.

"We are delighted to have signed this agreement with Helix for Klean-Prep(R), an important product, first launched in 1987," said Dr. Riccardo Braglia, Helsinn group's CEO, "and are pleased to strengthen our efforts to offering our network of partners, covering 85 countries world-wide, products which meet the medical community needs and which have a strong positive impact on patients' quality of life."